About MedBrief
Helping patients stay informed about the latest medical research — without spending hours on PubMed.
The problem
If you live with a chronic condition, staying on top of the research is hard. New studies come out constantly, but reading academic abstracts takes time, requires a medical background to interpret, and most patients simply don't have access to full papers behind paywalls.
Patient communities online are full of people asking “what does the latest research say?” — and getting answers that range from outdated to outright wrong.
What MedBrief does
MedBrief monitors PubMed and ClinicalTrials.gov daily for new studies on chronic conditions. When a new study is published, our AI reads it and generates a plain-English summary — what was studied, how it was conducted, key findings, and important limitations.
Every summary includes quality badges so you can immediately see whether you're reading about a small observational study or a large randomized controlled trial. No medical degree required.
You choose how often you want updates — weekly or monthly — and we deliver a digest directly to your inbox.
Our data sources
- PubMedThe world's largest database of peer-reviewed biomedical literature, maintained by the US National Library of Medicine.
- ClinicalTrials.govThe official registry of clinical trials maintained by the US National Institutes of Health.
We only include peer-reviewed studies with empirical data. Editorials, opinion pieces, and letters are excluded.
A note on AI summaries
Our summaries are generated by AI and reviewed by a second AI agent for accuracy before being published. While we take quality seriously, AI can make mistakes. All summaries include a link to the original study so you can verify anything that matters to you.
MedBrief is not a substitute for medical advice. Always discuss research findings with your healthcare provider before making any decisions about your care.
Beta phase
MedBrief is currently in free beta. All features are available at no cost while we gather feedback and improve the product. Beta users will receive a permanent 50% discount when paid plans launch.
Contact
Questions, feedback, or spotted an error in a summary? Reach out at contact@medbrief.org.